# RELMADA THERAPEUTICS, INC. (RLMD) · Edgar & Edgarette company card

> Relmada Therapeutics (RLMD) saw revenue fall 35.4% in FY2013 to $0 million, operating margin -878% against a -3.8% median for pharmaceutical preparations, equity -68.3% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1553643 · fiscal year ended 2013-08-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/RLMD) · [JSON](https://www.pops4.com/boards/company/RLMD.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $5,129 |
| Revenue growth, 1 year | -35.4% |
| Revenue growth per year | — |
| Operating margin | -877.7% (prior year -151.8%) |
| Net margin | -877.7% |
| Operating cash flow | −$11,859 |
| Capital spending | −$1,800 |
| Free cash flow | −$10,059 |
| Cash | — |
| Long-term debt | — |
| Total assets | $20,009 |
| Total equity | −$13,657 |
| Equity ÷ assets | -68.3% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$45.8M in FY2025); revenue is hard to predict: its 80% range is ±28%

## Edgarette's reading

Exposure: revenue $5K (FY2013). Experience: revenue down 35.4% on the year; operating margin -877.7%, down from -151.8%. Soundness: equity -68.3% of assets (liabilities exceed assets). Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $2K and $4K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -877.7% against a -3.8% median; growth -35.4% against 13.7%.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2025-12-15 ([filing](https://www.sec.gov/Archives/edgar/data/1553643/000121390025121461/0001213900-25-121461-index.htm))

## Recent filings

- 8-K · filed 2026-09-08 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1553643/000121390026097851/0001213900-26-097851-index.htm)
- 8-K · filed 2026-08-06 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1553643/000121390026086190/0001213900-26-086190-index.htm)
- 10-Q · filed 2026-08-06 · [filing](https://www.sec.gov/Archives/edgar/data/1553643/000121390026086151/0001213900-26-086151-index.htm)
- 8-K · filed 2026-07-28 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1553643/000121390026082007/0001213900-26-082007-index.htm)
- 8-K · filed 2026-05-28 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1553643/000121390026062184/0001213900-26-062184-index.htm)
- 8-K · filed 2026-05-12 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1553643/000121390026055164/0001213900-26-055164-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001553643.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1553643

## Cite

POPS4, Edgar & Edgarette: RELMADA THERAPEUTICS, INC. (RLMD) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/RLMD. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2013, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.